We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
-8.6%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$901M
AUM Growth
-$215M
Cap. Flow
-$32.4M
Cap. Flow %
-3.59%
Top 10 Hldgs %
51.77%
Holding
78
New
10
Increased
19
Reduced
15
Closed
15

Top Buys

Rank Stock Value
1
NVLN
Novelion Therapeutics Inc. Common Shares
NVLN
+$17.3M
2
HRTX icon
Heron Therapeutics
HRTX
+$16.5M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$13.9M
4
VCYT icon
Veracyte
VCYT
+$13.4M
5
ZBH icon
Zimmer Biomet
ZBH
+$9.22M

Top Sells

Rank Stock Value
1
NVDQ
Novadaq Technologies Inc.
NVDQ
+$43.2M
2
ANGO icon
AngioDynamics
ANGO
+$23.7M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$18.9M
4
DVAX
Dynavax Technologies
DVAX
+$14.1M
5
AEGR
Aegerion Pharmaceuticals
AEGR
+$13M

Sector Composition

Rank Sector Weight
1 Healthcare 96.52%
2 Miscellaneous 3.36%
3 Financials 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RPTP
76
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
– –
-664,800
Closed -$5.96M
1 2 3
4

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q4 2016 Portfolio in Review

As of Q4 2016, Broadfin Capital held 78 positions worth $901M, down 19% from $1.12B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Broadfin Capital withdrew a net $32.4M in Q4 2016, closing 15 positions and reducing 15 holdings. Its most notable exit was IVERIC bio, Inc. Common Stock, an estimated $18.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 92% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Broadfin Capital opened a new position in Novelion Therapeutics Inc. Common Shares worth $16.4M.

  • Broadfin Capital's largest Q4 2016 buy was Novelion Therapeutics Inc. Common Shares: 1,948,554 shares worth $16.4M.
  • Broadfin Capital added most to Heron Therapeutics in Q4 2016, an estimated $16.5M increase.
  • Broadfin Capital's biggest Q4 2016 reduction was Novadaq Technologies Inc., cutting an estimated $43.2M.
  • Broadfin Capital fully exited IVERIC bio, Inc. Common Stock in Q4 2016, selling an estimated $18.9M.
  • Broadfin Capital's ten largest holdings make up 52% of its $901M portfolio in Q4 2016.
  • Broadfin Capital opened 10 new positions and closed 15 in Q4 2016.
  • Broadfin Capital's portfolio value fell 19% quarter-over-quarter to $901M.

Based on Broadfin Capital's 13F filing for Q4 2016, filed 14 Feb 2017.